Side-by-side · Research reference
BronchogenvsDihexa
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/35 cited
BAnimal-StrongHUMAN-REVIEWED7/28 cited
Bronchogen
Tetrapeptide Bioregulator · Khavinson-School
Research models: tissue culture / parenteral
Dihexa
Angiotensin IV Analogue · Pre-Clinical
Not established — animal studies only
01Mechanism of Action
Parameter
Bronchogen
Dihexa
Pathway
Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration
HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization
Downstream effect
Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015Titova 2017
Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models
Feedback intact?
—
—
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework
Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015
Antibody development
—
—
02Dosage Protocols
Parameter
Bronchogen
Dihexa
Effective concentration (culture)
0.05 ng/mLZakutskiĭ 2006
Demonstrated in organotypic tissue culture of bronchial explants.
—
Treatment duration (animal)
1 month (30 days)Kuzubova 2015Titova 2017
Course duration in rat COPD models.
—
Evidence basis
Animal models (rat) / organotypic cultureTitova 2017Kuzubova 2015Zakutskiĭ 2006
No human clinical trials reported in available literature.
Pre-clinical / Rodent models
Tissue specificity
Selective for bronchopulmonary tissue
Part of Khavinson organ-specific bioregulator series.
—
Human dosing
—
Not established — no human trials
Animal studies
—
Mouse/rat models only — dosing not translatable to humans
Clinical status
—
No Phase 1, 2, or 3 trials published
04Side Effects & Safety
Parameter
Bronchogen
Dihexa
Animal safety profile
No adverse effects reported in published rat studies
Limited safety data; only animal models available.
—
Human data
Absent — no clinical trials in humans reported
—
Long-term effects
Unknown — maximum study duration 30 days in animals
—
Human safety data
—
None available — no human clinical trials
Theoretical c-Met risks
—
c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile
Pre-clinical tolerability
—
Not systematically reported in available studies
Absolute Contraindications
Bronchogen
—Dihexa
- ·Not approved for human use — research compound only
Relative Contraindications
Bronchogen
—Dihexa
- ·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
05Administration Protocol
Parameter
Bronchogen
Dihexa
1. Research context only
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
2. Animal model protocol
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017Kuzubova 2015
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
3. Organotypic culture
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006
—
4. Khavinson bioregulator tradition
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
—